CA2162045A1 - Electrochemical sensors - Google Patents

Electrochemical sensors

Info

Publication number
CA2162045A1
CA2162045A1 CA002162045A CA2162045A CA2162045A1 CA 2162045 A1 CA2162045 A1 CA 2162045A1 CA 002162045 A CA002162045 A CA 002162045A CA 2162045 A CA2162045 A CA 2162045A CA 2162045 A1 CA2162045 A1 CA 2162045A1
Authority
CA
Canada
Prior art keywords
membrane
erythrocyte
test strip
aggregating agent
porous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002162045A
Other languages
French (fr)
Inventor
Murdo Black
Long Lin
James Guthrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medisense Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2162045A1 publication Critical patent/CA2162045A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D69/00Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/06Flat membranes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D69/00Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/14Dynamic membranes
    • B01D69/141Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/002Electrode membranes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3272Test elements therefor, i.e. disposable laminated substrates with electrodes, reagent and channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002Partitioning blood components
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/40Semi-permeable membranes or partitions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/817Enzyme or microbe electrode
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/969Multiple layering of reactants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/97Test strip or test slide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Abstract

Erythrocyte exclusion membranes suited for test strips of electrochemical sensors have a porous matrix and a mobile erythrocyte aggregating agent. The membranes typically comprise a water-insoluble hydrophobic polymer incorporating a hydrophobic polymer and with the erythrocyte aggregating agent. Such membranes can have a pore size which is several times layer than the diameter of erythrocytes, and allow rapid passage of plasma by holding back the erythrocytes as rouleaux at the surface of the membrane. The membranes are preferably made by forming in situ on a test strip using spray casting.

Description

2~62~4~

ELECTROCHEMICAL SENSORS

Introduction The present invention relates to electrochemical sensors, and more particularly but not exclusively to electrochemical biosensors. The present invention further relates to a method of manufacture of test strips for use in such sensors.

Background of the Inventio~

There is an increasing public awareness of the diagnostic significance of levels of components in the blood and other body fluids, and many sensors are designed for non-expert use. A particular goal is the provision of electrochemical sensors which do not require elaborate preparation of a test sample, and can rapidly give a result merely by application of the body fluid to a test strip. Good sensitivity is achieved usually with a biochemically specific reaction, such as by enzymatic catalysis of a reaction of the component to be detected. The reaction results in transfer of charge which can be q~l~lit~tively or 4~ ely detected, for instance by an amperometric procedure.

Amperometric biosensors for p~"rwlll~.lg diagnostic tests for components of body fluids are described, for exarnple, in US Patent 4545382, European Patent 127958 and European Patent 351891. Such devices offer the facility for rapid, convenient and specific measurements of analyte components in blood by lay users, and a sensor for glucose is commercially available as the MediSense ~ ExacTech g) sensor.
.

Whole blood is a complex, predomin~tely aqueous mixture cont~inin~
dissolved gases, simple dissociated and hydrated ions, materials in colloidal or other form of solution, small scale cellular debris, and living cellular components including red blood cells, the erythrocytes. It is WO 94/27140 21 ~ 2 Q~ 5 2 PCT/GB94/01011 sometimes difficult to achieve reproducible analytical results with electrochemical sensors when using whole blood samples. Varia~ions in red cell concentration, the h~em~tocrit, is the main contributor to inaccuracies in using whole blood samples for electrochemical sensors.

Accordingly, there is a need to develop improved electrochemical sensors which are less dependent on the h~em~tocnt of the blood. To this end, there have been proposals for overlay membranes which serve to exclude erv~rocytes so that the sensor itself is only contacted by blood plasma.
Illustrative examples of proposals for erythrocyte exclusion membranes are to be found in published EP-A 289269 and other patent literature.

There are difficulties in developing a s~ti~f~etory ery~rocyte exclusion membrane suited for test strips such as amperometric electrode test strips.
A hurn~n erythrocyte is deformable in vivo to pass through lllmin~l di~meters as small as 2 or 3 ,um, and thus membranes of this porosity are ineffective, either because the erythrocytes leak through by deformation or bec~llee the erythrocytes plug the pores to prevent passage of the plasma.
Where the porosity is further re~llce~l, the transport of plasma is difficult.
In this respect, the typical volume of the blood sample for an amperometric glucose test is only 20 ~1 and yet gravity has to provide the principal driving force, with capillary forces providing only a secondary driving force. Given the goal of m~ or redueing me~ellrement times, where the period for a complete glucose test is typically 30 seconde, rapid transport of the plasma through the membrane is needed.

Thus, the transport of the plasma requires an open membrane structure, while the sep~dlion of erythrocytes ~ n~le a closed membrane structure. In t~e light of these contradictory requirements, it becomes clear that conventional membrane systems are not entirely suitable.

US Patent 5,055,195 describes the use of retention substrates which bring about strong co~ hon of blood so that the corpuscular components are effectively retained in a paper or glass fibre fleece and are sepalated from the plasma. This object is achieved by using retention substrates which contain two strongly polar groups which are connected by a non-polar bridge. The retentio~ substrates are preponderantly dyestuffs, and they bring about random clurnping.

2~

Objects of the Invention An object of the present invention is provide an improved erythrocyte exclusion membrane for an electrochemical sensor. In this respect, it is an object to provide an improved porous erythrocyte exclusion membrane which permits rapid transport of plasma through the membrane, while subst~nti~lly excluding the passage of erythrocytes. A particular object is the provision of a disposable single-use electrode test strip for an amperometric biosensor, for use with a sample of whole blood, which is less dependent on the haematocrit of the blood.

A related object is to provide a new method for the m~nllf~cture of test strips.

S~lmm~ry of the Invention According to the present invention, there is provided an erythrocyte exclusion membrane comprising a porous matrix including an erythrocyte aggregating agent.

The erythrocyte aggregating agent is an agent which can induce the formation of erythrocyte aggregates known as rouleaux. Such rouleaux have a diameter of typically 50 to 100 times that of an individual e~throcyte, and are not r~n~lom clumps. Accordingly, with the inclusion of the erythrocyte aggregating agent, the porosity of the membrane can be such that individual erythrocytes might otherwise pass through the matrix, but rouleaux can not pass through the matrix. The ery~rocyte aggregating agent is present at or migrates to the surface of the membrane to bring about formation of the rouleaux. In this way, the erythrocytes are held outside the membrane pores, allowing effective transport of the plasma with separation ~om the erythrocytes.

Thus, the present invention provides a test strip for an electrochemical sensor for contact with whole blood in order to effect an electrochemical measurement. The test strip has an exclusion layer in the form of a porous membrane with an erythrocyte aggregating agent. The membrane excludes red blood cells from contact with the sensing electrodes by WO 94/27140 ~ 2 ~ 4 4 PCT/GB94/01011 aggregating them at the surface of the membrane and excluding them as e~hrocyte rouleaux. By virtue of the presence of the exclusion laver, the sensing electrodes are exposed only to plasma, so that the red blood cells can not i~llelfere. In this way, reproducible results are more easily achieved, even for disposable test strips made in high volume and at low cost.

Preferred Embodiments The l,refelled porous matrix ofthe polymeric membrane mainly consists of a water-insoluble hydrophobic polymer so that this matrix will not be si~nificantly altered by the water present in whole blood. However, membranes con~i~ting of such material have poor wethng ability. In order to obtain effective plasma transport through the membrane pores, the porous hydrophobic matnx ~fe,ably incorporates a hydrophilic polymer.

A ,~)rer~lled membrane thus comprises at least three groups of polymeric materials, namely a hydrophobic polymer, a hydrophilic polymer, and a mobile erythrocyte aggregating agent.

The hydrophobic polymer is a water-insoluble but organic solvent-soluble membrane-forming polymer which provides the desired porous membrane structure. Such polymers are well known and typically contain hydrophobic functional groups at a ~lomin~nt level, though a rninor proportion of hydrophilic fimctional groups can be present. F.~mples of the hydrophobic polymer include cellulose acetate propionate, cellulose acetate, polyvinyl butyral, polystyrene, etc.

The hydrophilic polymer is a water-soluble and organic solvent-soluble polvmer which provides good membrane permeability to plasma and especially dissolved analytes in the plasma. Such polymers are well known and typically contain hydrophilic fi~nctional groups at a dominant level, though a minor proportion of hydrophobic functional groups can be present. Examples of the hydrophilic polyrner include hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, etc.

2l62o~
~ WO 94/27140 - PCT/GB94/01011 The e~throcyte aggregating agent is suitably a water-soluble and organic solvent-soluble component, typically polymeric, which can easily be released and dissolved into blood plasma when it is brought into contact with the blood. Such a material induces and accelerates erythrocvte aggregation as rouleaux at the surface of the membrane, thus preventing the erythrocytes from passing through the membrane. Examples of the erythrocyte aggregating agent which act as a mobile erythrocyte aggregating agent include dextran and positively charged polymers such as polylysine salts, polybrene (that is, hexamethrine bromide), protamine, etc.
It is l~,efelled that the e~ythrocyte aggregating agent is more soluble in water than the hydrophilic polymer, in order that the erythrocyte aggregating agent is the first component to dissolve and can rapidly induce formation of the rouleaux.

The relative amounts of the three components are chosen on the basis of the desired properties of the membrane such as the porosity and hydrophobicity. A ylert;lled range for the weight ratio (hydrophobic polymer): (hydrophilic polymer) is from 3:1 to 1:3, more yrefelably from 2:1 to 1:2, and most yrerel~bly from 3:2 to 2:3. Thus, the typical membrane contains about equal amounts of the two types of polymer.

The erythrocyte aggre~ing agent is usually a minor component of the membrane, and yrefclably comprises from 5 to 45 % of the membrane, more yrefel~bly from 10 to 40 % and most p~r~l~bly from 25 to 35 %.
Thus, the typical membrane contains about 30 % of the erythrocyte aggregating agent.

Other components may be included in the membrane, such as surfactants to improve wetting, or plasticizers such as dioctyl phth~l~te.

In the l,re~lled membrane there is a generally homogenous distribution of heterogenous polymeric components with the mobile erythrocyte aggregating agent located inside a polymeric network of interconnecting porous pathways through the membrane. In l"e~lled embodiments, the pore diameters are in the range l to 15 ,um, more ~refel~bly 3 to 15 ,um.
One of the features of this invention which ~ tin~ hes this membrane system from other membranes is the characteristic of sep~ g WO 94/27140 21~ 2 ~ 4 5 6 PCT/GB94/01011 erythrocytes from whole blood even when the pore size of the membrane is significantly larger than the maximum diameter of the erythrocytes.

A proposed mech~ni~m for erythrocyte separation by the preferred membrane is described as follows, though we are not bound by this theory.
After whole blood is brought into contact with the membrane, the plasma wets across the membrane surface and soaks into the hydrophilic polymer, m~kin~ it swell to reduce the membrane pore size. At this initial stage, the erythrocytes are held outside the membrane pores, transport of plasma through the membrane is relatively slow, and the erythrocyte aggregating agent is mobilized and forced out from the membrane pores into the plasma. The mobile erythrocyte aggregating agent has high solubility in the aqueous phase and dissolves into the plasma faster than the hydrophilic polymer, ini~i~ting the formation of rouleaux. The plasma then wets through the hydrophilic material to give more swelling and to release more erythrocyte aggregating agent which accelerates the process of erythrocyte rouleaux formation, to stop the erythrocytes from penetrating the membrane. W~en most of the erythrocyte aggregating agent has dissolved7 the hydrophilic material starts to dissolve into the plasma, effectively opening up the membrane pores to allow faster transport of the plasma. At this stage, the size of the membrane pores may be larger than that of an individual erythrocyte, but by this time most erythrocytes have become erythrocyte rouleaux and the membrane is therefole still capable of holding the erythrocytes outside the membrane pores to prevent fouling of the membrane pores which occurs with most of the convenhonal procedures for membrane se~ lion.

The membranes of the present invention are especially suited for use in electrode test strips for an electrochemical sensor. Such a sensor, for example for amperometric or potentiometric detection~ ~pically employs a dry throw-away electrode test stnp . The electrodes ~refef~bly comprise electrode areas formed for instance by screen printing or other suitable technique. Reference is made to EP-A 127958, 184895, 230786, among other published European Patent Specifications in the name of MediSense, Inc., formerly known as Genetics International Inc., and the disclosures of these three European Patent Specifications are incorporated for their teaching of m~nllf~cturing methods and constructional features. The %1~2Q~
WO 94/27140 7 . PCT/GB94/01011 membrane of this inventiOn for an amperometnc electrode test strip usuallv has a thickness in the range 20 to 50 ~m.

The membrane is preferably formed in situ on the strips.

As an example of the in situ procedure, the membrane can be made by spray casting. With c~ctin~ the membrane will be formed in intim~te contact with the strip surface. There are other advantages in casting or coating of the polymer solution directly on the strip surface by spraving a polymer solution followed by evaporation of the solvents. With such a technique, it is possible to control the porosity of the membrane, notably by selection of solvents and spraying conditions. Moreover, the possibility of deactivating the enzymes can be greatly reduced, since unlike dip-coating the polymer solution re~chin~ the electrode surface contains lower levels of solvents.

The membrane components are dissolved in a mixed solvent and mLxed thoroughly. Depending on the characteristics of the polymeric materials, the membrane c~stin~ techniques and the desired membrane morphology, di~elent solvent systems are used. The polymers, the mixed solvent system, the mixin~ ratio and the membrane deposition method and conditions are usually selected so that a membrane is obtained which is characterised by its homogeneity and the luli~o~m distribution of micropores, ~refer~bly within the size range 1 to lS~m. The porosity will typically reflect the spraying llict~nce, the spray pressure, and the volatilityof the solvents. In particular, larger pores are produced as the spraying distance is re-lllce~l and, correspondingly, smaller pores are produced as the spraying di~t~nce is increased. The thickn~ss of the membrane can be controlled as desired and depends on the polymeric materials, the concentration of these materials in the continuous medillm and the manufacturing conditions.

The resultant ~refe~ed membrane structure is distin~iche-l by the distribution of three polymeric components. The hydrophobic polymer forms the porous structure, and the other polymers coat the surface of this r structure. In this way, the blood sample spreads rapidly over the membrane. The rapid transport is facilitated by the porous structure and hydrophilic properties of the surfaces. In other words, the hydrophillic -WO 94/27140 2 ~ 2 a ~ 8 PCT/GB94/01011 functional groups facilitate the wetting of the surface while the rnicropores provide a path for the diffusing con~titl-ents.

Techniques apart from spray casting can be used. For instance, the membrane can be separately made as a sheet for fixing to strips duIin~
manufacture of the strips. As an example of the separate sheets, the membrane can be made by dip coating of a porous support, for example a mesh such as nylon mesh, or a web of non-woven polyester. The porosity will typically reflect the relative amounts of the membrane components, the choice of solvent, and processing such as water-rinsing. The polymeric components can be sprayed or applied by inkjet or pulsejet printing, needle dosing, rollercoating, printing, and similar techniques.

Membrane solutions can be cast onto the tranquil surface of a bath of non-solvent for the membrane polymers. A polyrneric membrane forms when solvents evaporate from the membrane solution. The final membrane is obtained by removing the polymeric membrane from the non-solvent bath and drying it in air.

Membrane solutions can also be cast onto the surface of glass plate to allow the solvents to evaporate into the air. A polymeric membrane is obtained when most solvents evaporate. The dried membrane can easily be detached from the glass plate with the help of a silicon spray on the glass plate before c~ctin~

Membrane solu~ions can also be ~iirec~ly cast onto the object surface using printing techniques.

The Drawings The invention will be further described by way of exan~ple with refel ~nce to Figures 1 to 4 of the accompanying drawings, in which:

Figure 1 shows in diagr~mm~hc cross-section a first embodiment of the invention;
Figure 2 shows an exploded perspective view of a second embodiment;

~ WO 94/27140 ~16 2 0 ~ 5 PCT/GB94/01011 Figures 3 and 4 shows al,palalUs for spray c~tinE employed in the F,x~mples;
Figure S shows in diagr~mm~tic cross-section a third embodiment of the invention; and Figure 6 shows in diagr~rnm~tic cross-section a fourth embodiment of the invention.
.

Figure 1 shows a dry disposable electrode test strip 10 for use as part of an amperometric test sensor. A PVC substrate 1 1 carries carbon tracks 12 overlain with silver tracks and coated to form a working electrode 13 and a reference electrode 14 which are covered by a membrane 15. The carbon tracks form contacts for connection of the strip to readout al~a~ s, and are coated with a silver conductive ink to improve the conductivity of the carbon. In use, a drop of blood 16 is applied to the surface of the m~mbrane.

Figure 2 shows a second embo-liment of the invention. A PVC substrate 21 of a test strip 20 carries carbon tracks 22 overlain with silver tracks 23 and coated to form a working electrode 24 and a fe~lence electrode (not visible) which are covered by a membrane 25. In this case the test strip 20 has an outer coat 26 as a non-porous humidity barrier. An aperture 27 in the humidity barrier forrns a target s~mple application zone, for the application of whole blood. Blood applied to zone 27 wicks under coat 26 through a pe~ ble m~tP~ 28 to m~mhrane 25 where plasma components rapidly penetrate and wet the electrodes.

The confi~lration of Figure 2 not only acts as a barrier to red blood cells, but also re~1lces the effect of en~/iro~ ental factors on the strip response.

In Figures 3 and 4, a~au~ s for spray c~cting of the membranes employs an air brush 30, driven from a compressor 31. In this in~t~nce, the air brush 30 was stationary and a card 32 of multiple electrode strips was mounted on a metal rail 33 driven by an adjustable motor 34. The electrode card 32 was covered by a stencil 35 to give deposition of the membrane polymer solution onto the intended electrode sen~ing area.

WO 94/27140 216 2 0 ~ ~ lo PCT/GB94/01011 In the embo~liment of Figure 5, the construction is as shown in Figure 1, except for the provision of the membrane in the form of a nylon mesh 36 dip-coated with polymer solution.

In the embodiment of Figure 6, the construction is as shown in Figure 1, except for the provision of the membrane as two polymer layers 37, 38.

Examples of The Invention Example 1 Electrode test strips for cholesterol were made in accordance with EP-A
230786, using screen printing. In this m~nllf~ctnring process, multiple electrodes were screen printed onto a large sheet of carrier material, which was then subdivided to give individual test strips. The screen-printing process comprises the following steps;
a) printing of a conductive tracking b) printing of a working electrode c) printing of a reîerence electrode, and d) printing of a dielectric in~nl~t~on The working electrode was prepared from commercially obtained horse radish pero~ se, cholesterol oxidase, cholesterol esterase, sodium cholate and binder. These were reco~ (e~ in an imitl~7.ole buffer mLx of pH 7 for 2 hours prior to the addition of finely divided carbon and 1,1'-dirnethylferrocene ethanolamine as me~ tor. The working electrode was screen plinted onto the l~rep~ ted carbon track. The mix was allowed to dry.

Batches of the electrode test strips were provided with membranes in accordance with the present invention. The reslllt~nt electrodes collfolllled with the construction shown in Figure 1. The conductive carbon tr~çkinE for each electrode was screen-printed onto the surface of the substrate in two conductive tracks of 45 mm by 2 mm, with a separation of 3 mm. The membrane was spray coated over the electrodes.
Where desired, the test strips can be with the construction shown in Figure ~i 620~

2, with a surfactant coated nylon mesh as permeable material 28 and a humidity overlayer 26 applied over the membrane.

For the spray-casting of the membrane, polymer solutions were spray-cast onto the surface of the electrodes as part of the m~nllf~ctuIing process.

The step of spray-c~tin~ was carried out using the apparatus of Figures 3 and 4, with an air brush (Badger Model 200, Badge Air-Brush Co., Illinois), driven from an oil-free air compressor (Pioneer 200, Clark International, London). The distance between the spray nozzle of the air-brush 30 and the electrode card 32 and the vertical position of air-brush 30 was set up to be easily adjusted, it being recognised that this distance affects the evaporation of solvent and thus the structure of the cast membrane. The typical spray-casting parameters used for the membrane coating were as follows:

Distance between the spray nozzle and the targeted electrode surface:
18 cm Electrode movement: 125 cmlmin Number of spray passes: 2 A mlmber of polymeric materials were investigated for their suitability as the membrane materials for the membranes. T~e following polymeric materials showed particularly promi~in~ characteristics:

Hydrophobic polymer:
Cellulose acetate propionate ~CAP F.~ n Chemicals, Kingsport, Tennessee, USA) Poly(vinyl butyral) (B-72 or B-79, Butvar, Monsanto Ltd., St. Louis, Missoun, USA) Hydroxyethyl cellulose (Natrosol 250 mR, Aqualon UK Ltd., Chester, UK) Hydrophilic polymer:
Hydroxypropyl cellulose ~Klucel HPC L, Aqualon UK
Ltd., Chester, UK) WO 94/27140 PCT/GB94101011 ~
2162~45 12 Poly(vinyl alcohol) (Aldrich Chemicals Co. Ltd., Gillin~h~n~, Chester, UK) Erythrocyte aggregating agent:
Dextran 3759 (Sigma Chemical Co. Ltd., Poole, Dorset, UK) Ethyl acetate was found to be a possible solvent. However, CAP/HPC
solutions in ethyl acetate have a milky appearance and a second solvent is needed, in order to provide an entirely miscible polymer solution cont~inin~ CAP/HPC. Ethanol and meth2nol were found to suitable.
Methanol gives a true solution of CAP/HPC at a much smaller presence in the solvent lllixLule than does ethanol. It was ascertained that the optimal ~mount of methanol in the polymer solution was 8%. This amount of methanol when combined with 82% of ethyl ~cet~te, 5% of CAP and 5%
of HPC gives a clear solution of CAP/HPC with low viscosity and good processability.

A~lo~liate amounts for a 5% solution of each of the polymers CAP and HPC were added to the solvent ~xlule in a ball-millin~ jar. Complete solution of the polymers in the solvent ~ e took about 30 minlltes under stirring. An a~ u~liate arnount of dextran was milled in a mortar to reduce the particle size to around 50 ~m and then mixed into the polymer solution. This l~ e was then milled with ceramic milling balls until the dextran particle size fell below 20 ,~Lm. In the resl-lt~nt polymer rruxture, the ratio CAP: ~C: dextran was 3.6: 3.6: 0.7. Initially, this ure too high a viscosity for spray application, and the polymer solution/cornposition was then ~1ihltel1 with ethyl ~cet~te/meth~nol (90%/10%). The co~tin~ were deposited onto the electrode surfaces using the equipment. The membranes were then dried. The performance of the membrane-coated cholesterol electrodes were then assayed.

Drawing on this initial work, polyrner solutions co~ valious compositions of CAP, HPC, dextran, ethyl acetate and methanol were prepared. These polymer solutions were cast onto the sensing area of cholesterol electrodes. In general with the spray procedure, there was some difficulty in achieving reproducible homogenous coating.

From this work, the optimal formulation, which gave the best membrane morphology and membrane transport performance, is given in the following table.

Materials Composition(%) CAP 3.6 E~C 3.6 Dextran 0.7 Ethyl acetate 82.8 Methanol 9.3 The resultant mçmbrane had an average pore size of 4 ,um, as determined by sc~nnin~ electron microscopy.

In a side experiment, the formulation was spray coated onto filter paper and dried. A stainless steel weight with a drilled 4 mm central hole was put on the filter paper. The membrane-coated paper with weight were placed on a sheet of uncoated filter paper. A 15~1 blood sample was added to the hole and left for 15 secorlrl~. The underlying uncoated filter paper was then evaluated for erythrocyte break-through, and found to be straw coloured. This result indicates that only plasma passed through the membrane, with the main driving force being gravity.

In order to study the transport properties of the membrane cast on the electrode s~ ce, membld~c co~te~1 electrodes were ev~ te~l using blood samples. A range of blood samples with h~e ~ ocrits varying between 30% and 60% PCV (packed cell volume) and constant cholesterol were tested. Electrodes were either uIlcoated, or coated with of membrane either S,um or 10~un thick.

The i-t transients were recorded and integrated over 40 to 60 seconds.
The following data for di~,rent b~tches of electrodes were obtained:
m~tocrit regression -V-,lLC response slope regression CV(%) uncoated -0.355 0.817 2.56 coated (5~m) 0.026 0.029 8.86 coated (5,um) -0.076 0.227 2.74 WO 94/27140 7, ~ ~ % ~ ~5 14 PCT/GB94/01011 coated (10~Lm) -0.018 0.056 3.22 coated (10~m) 0.015 0.023 6.9 All of the electrodes with the membrane thus gave a negligible haematocrit effect.

Fx~mple 2 It was found that the morphology of the membranes of Example 1 was sometimes sensitive to the parameters associated with the spray operation.
Considering that an optimized industrial process needs relatively low sensitivity to the process parameters, alternative membrane formulations were designed.

A solvent blend which contains acetone, methanol and mesitylene was found to be more suitable. Acetone and methanol were used as solvents for CAP and HPC respectively. Acetone evaporates first into the air when the membrane solutions are cast onto the electrode surface. As a result of this acetone evaporation, CAP in the membrane solution is transformed from a gel-phase into a solid phase. The solid-phase CAP
forms the skeleton of the membrane structure. The ~leci~ Lion of HPC
is slower than that of CAP bec~-lse HPC is retained in methanol which evaporates slower than ~cetone. The.~fole, the CAP-~cetone system ~ives a ~ porous structure. The HPC deposits on the s~ ce of the primary membrane pores.

Mesityle~e was used as a pore-former in ~e membrane. Mesitylene is a non-solvent to the CAP, HPC and dextran. Mesitylene has a much higher boiling point than either acetone or methanol. Thus, it rem~in~ in the membrane for a longer time than acetone or methanol. This enables mesitylene to be a good former of secondary membrane pores.

A typical formulation for a membrane solution is as follows:

Cellulose Acetate Propionate 1.25% POLYMER 1 Klucel Hydroxypropyl Cellulose 1.25% POLYMER 2 Dextran MW 87,000 g/mol 0.25% POLYMER 3 ~ = ~ ==
2~6204~

Surfactant (Fluorad FC 1 70C, 3M Company Commercial Chemicals Division, St. Paul, Minnesota, USA) 0.25%
Acetone 43.5%
Methanol 43.5%
Mesitylene 1 0.0%

The resultant membrane when using a spraying dist~nce of 4.0 cm had an average pore size of 7 !lm, as determined by sc~nning electron mlcroscopy.

Apart from cellulose acetate propionate, there are many hydrophobic polymers with good solubility in organic solvents which can be used as the POLYMER 1 in the membrane form~ tion- These polymers include cellulose acetate, polyvinyl butyral, polystyrene, etc.

Alternatives to the hydroxypropyl cellulose, which can be used as the POLYMER 2 and have good solubility in organic solvents include polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl ~cet~te, etc.

There are ~ltç~ ~ve polymers apart from dextran, which can be used as POLYMER 3 in the membrane formulations. These polymers should have high molecular weights, good hydrophilicity and should be soluble in organic solvents. Some positively cllalged polymers with good hydrophilicity and with modest to good solubility in organic solvents can also be used. These alternatives to dextran include polylysine, polybrene, .ot~i~le, etc.

F~r~mple 3 The main advantage of plasma se~tion is a reduction in the red cell elrere.~ce on the sensor electrodes. This illle-r~rence is due to diffilsional limit~tion and some interfering reaction. Wi~ increasing haematocrit there is a reduction response at the sensor electrode at a constant analyte concentration. With an effective red cell exclusion membrane a reduced haematocrit response is expected.

wo 94/27140 21 6 2 04 5 16 PCT/GB94101011 Electrode test strips for glucose were made in accordance with EP-A
127958, using screen printing. The m~nl;~f~cturing process was much the same as that described in Exarnple 1 for the m~n~lf~cture of electrode test strips for cholesterol, except that the working electrode was prepared from commercially produced glucose oxidase and binder. These were reconstituted in BES buffer pH 7.4 for 2 hours prior to addition of ultrafine carbon and l,l'-dimethylferrocene ethanolamine as mediator.

Batches of the strips were sprayed at different distances with the formulation of Example 2 to form membranes of di~rellt pores sizes.
The following results for glucose sensors in accordance with EP-A
127958, with and without membranes, show the relative reduction in h~em~tocrit response, corrected for glucose sensitivity.

Spraying Membrane Relative E~em~tocrit Distance (cm) Pore Size (,um) Response (%) Uncoated 1 00 electrodes Membrane coated 3.5 10 45.4 electrodes Membrane coated 4.0 7 23.3 electrodes Membrane coated 5.5 2 33.1 electrodes In this experiment the 7 ~m pore size membrane gave the greatest reduction in relative h~m~tocrit sensitivity.

Example 4 The dip-coating technique was also used to produce membranes for test strips for glucose sensors in accordance with EP-A 127958. The construction of the resultant test strip is illustrated in Figure 5.

Nylon mesh was dipped into the polyrner solutions to allow the nylon mesh to be coated with the polymer solution. The coated nylon mesh was then removed from the polymer solution and allowed to dry. These 21620~

procedures gave a ullifol~ polymeric membrane on the nylon mesh. In fine-tuning the membrane morphology, rinsing and then washing of the dip-coated nylon mesh with water, to give more porous membrane morphology was carried out.

A typical polymer solution used for dip-coating the nylon mesh is givenbelow, and cont~ined CAP, ~'C, tetrahydrofuran (T~), cyclohexanone and dioctyl phth~1~te. In this solution, CAP, the major membrane material, formed the rigid skeleton of the membrane system. HPC
contributed to the formation of microporous structure and to the hydrophilicity of the membrane system. By altering the ratio of CAP and HPC in the polymer solution, it is possible to control the porosity of the membrane structure. THF is the major solvent used in the polymer solution. T~ plays an important role in inllur.in~ the L~ ;on of a microporous m~.mbrane structure. Under the e~c.;... ~l~1 conditions, it was found that the evaporation rate of the THF was high, and there was some difficulty in obt~inin~ membranes of w~irOllll thickness.
Cyclohexanone was used as a minor solvent for CAP and for HPC. By altering the ratio of the THF and cycloh~x~none, the solvent evaporation rate was controlled to a s~ti~f~ctory degree to achieve a membrane of accurate thiçkness. The porosity increæed with increasing amounts of cyclohe~none. Dioctyl phth~l~te was used to provide plasticity to the membrane s¢ucture. This was bec~llse a membrane con~i~tinE of CAP
and HPC can be brittle. Dioctyl phth~1~te wæ çhosen in this context bec~llce its physicochemical nature allows it to assist the diffusion of plasma through t~e membrane.

Nylon mesh was dipped for a few seconds into the polymer solutions.
The mesh was then rinsed with water at ambient temp~lule for 5 seconds to induce the precipitation of CAP and the extraction of part of the HPC
from the membrane assembly. The system was then dip-coated with a mixture of !% dextran, 1% surf~ct~nt and water at ambient ~empc~ re, and dried in air. In the dip-co~in~ technique used in this study, the water rinse was designed to induce the precipila~ion of CAP and to dissolve part of the HPC cont~ined in the cast polymer solution, to improve the efficiency of plasma transport. The water rinse helps the forrnation of the porous swcture in the membrane, to provide desired hydrophilicity. The WO 94/27140 21~ 6 2 0 ~ ~ 18 PCT/GB94/01011 coated nylon mesh was then fixed onto the electrode surface of both the cholesterol electrodes and the glucose electrodes.

Polymeric materials were investigated for their suitability as ingredients in a dip-coating formulation. A prefelled dip-coating membrane formulation was found to be as follows:

Polymer %
CAP 2 Polymer 1 E~'C 2 Polymer 2 THF 85 Solvent 1 Cyclohexanone 4 Solvent 2 Dioctyl phth~l~te 7 Additive The surface morphology of a typical dip-coated nylon mesh membrane was ~x~...;.,ed by sc~nning electron microscopy, showing porous structures with an average pore size of 4 ~lm.

Screen printed sensors for cholesterol were plc~alcd in accordance with EP-A 230786, with and without the dip-coated membrane.

On testing it was found that the cholesterol electrodes with membrane gave higher electrode cull~nls than the cholesterol electrodes without membrane, and higher values i-t integration.

From statistical analysis of the data, it was concluded that the me~llbla.le cholesterol electrodes have higher sensitivity to the cholesterol than do the ordinary cholesterol clc. lsodes. This is in-lic.~te-l by the higher slope of cholesterol calibration line for the membrane cholesterol electrodes (10.539) than that for the ordill~y cholesterol electrodes (5.412).

Tests for the h~P.~ ocrit effect were carried out on the ordi,l~y cholesterol electrodes and the cholesterol electrodes covered with dip-coated membranes in order to evaluate the ability of the membrane to separate erythrocytes from blood samples. The blood samples were as follows:

Sample 1: E~em~tQcrit level = 36%

æ~o4~

Cholesterol concentratiOn = 6.98 mM.
Sample 2: ~em~tocrit level = 44%
Cholesterol concentration = 6.98 mM.
Sample3: Haematocr~tlevel = 54%
- Cholesterol concentration = 6.98 mM.

The i-t transients were obtained and integrated over the period 27~0 seconds, in order to carry out haematocrit effect analysis. The average statistical pararneters for the tested batch associated with the haematocrit effect lines are given in the next table.

ElectrodeType Slope s Intercept ~i R
No Membrane -0;137 0.051 21.725 2.306 0.5982 Membrane -0.072 0.124 19.648 5.478 0.2510 From the table, it can be concluded there is a reduced h~em~tocrit effect using the dip-coated nylon meehes. There is a re-lnction of the absolute value ofthe slope ofthe h~P..,~tocrit effect lines from 0.137 (for t_e or~li,l~y cholesterol electrodes) to 0.0721 (for the mçmbrane-treated cholesterol electrodes).

Fx~mple 5 Dextran has limite~l solubility in many organic solvents. Another ~ploach to the incl~leion of dextran in the membrane assemblies is spray-c~etin~ of a two-layer, membrane assembly. The idea involves spray-c~etin~ a polymer solution co~ CAP and HPC as the first membrane layer followed by spray-c~etin~ a polymer solution co~ dextran on top of the first membrane layer. The construction of the resl-lt~nt test strip is illustrated in Figure 6.

The hydrophobic polymer and the hy~o~ ilic polyrners can be prepared for the c~tin~ of the first membrane layer. The erythrocyte aggregating agent material, dextran, can be dissolved in ethylene glycol to give the polymer solution for the casting as the second membrane layer. Polymer solutions either cont~ining both ~'C and dextran were l,re~aled. Since ethylene glycol has too low a volatility, a l~ixLule of ethanol and ethylene glycol was use~als ~e so~vent in preparation of the solution for the second membrane layer.

Membranes with different contents of dextran were prepared. These membranes consisted of two membranes layers each approximatelv 5 to 10 ~m in thickness. The first membrane layer contained 50% of CAP and 50% of HPC. The second membrane layer cnn~i~ted of dextran and HPC.
The composition of dextran in the second layer was varied to allow assessment of the function of dextran in the separation of erythrocvtes.
The fo~ tions of the polymer solution for c~stin~ of the second membrane layer are given in the next table. These polymer solutions contain 90% of ethylene glycol.

Solutions Compositions (%) Dextran HPC
0.0 10.0 2 2.5 7.5 3 5.0 5.0 4 7.5 2.5 0.0 The cholesterol electrodes, coated with the CAP/HPC (50%:50%, first layer) and dextran/~C (secon~ layer), were tested for their ef~iciency in se~ g e~rocytes and in tran~o~ g cholesterol.

Whole hllm~n blood samples were used, as follows:
Sample 1: ~tn~tocrit level = 32%
Sample 2: E~m~tocrit level = 34%, Sample 3: H~tn~tocrit level = 48%.

The i-t transients were integrated over the period of 15-30 seconds, and from ~e SD values, it can be concluded that the i-t transients obtained have s~ti~f~ctory overall reproducibility.

The h~em~tocrit effect lines were plotted, giving the following data.

2~ q5 WO 94/27140 21 ` PCT/GB94/01011 Dextran (%) Slope ~s Intercept ~i R
- 0.0 -0.427 0.045 30.055 1.886 0.984 2.5 -0.156 0.048 20.028 1.971 0.916 5.0 -0.003 0.141 17.350 5.751 0.010 7.5 -0.044 0.120 18.987 4.899 0.180 10.0 -0.052 0.025 14.360 1.040 0.822 These results shown the ability of dextran to facilitate the exclusion of eIythrocytes, as demonstrated by the decrease in absolute value of the slopes from 0.427 to 0.003.

Claims (16)

WE CLAIM:
1. An erythrocyte exclusion membrane for a sensor, said membrane comprising a porous polymeric matrix and a water-soluble erythrocyte aggregating agent.
2. The membrane of Claim 1, wherein said porous matrix comprises a water-insoluble hydrophobic polymer and a water-soluble hydrophilic polymer.
3. The membrane of Claim 1, wherein said porous matrix comprises pores of pore diameters in the range 1 to 15 µm.
4. The membrane of claim 1, comprising a single layer.
5. The membrane of Claim 1, comprising first and second layers, said first layer comprising said porous matrix and said second layer including said erythrocyte aggregating agent.
6. The membrane of Claim 1, further including a porous support.
7. The membrane of Claim 1, wherein said hydrophobic polymer is selected from the group consisting of cellulose acetate propionate, cellulose acetate, polyvinyl butyral and polystyrene.
8. The membrane of Claim 1, wherein said hydrophilic polymer is selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol and polyvinyl acetate.
9. The membrane of Claim 1, wherein said erythrocyte aggregating agent is a mobile erythrocyte aggregating agent selected from the group consisting of dextran, polylysine salts, polybrene, and protamine.
10. The membrane of Claim 2, wherein said erythrocyte aggregating agent is more water-soluble than said water-soluble hydrophilic polymer.
11. The membrane of Claim 1, wherein the pores of said porous polymeric matrix have pore diameters in the range 1 to 15 µm.
12. The membrane of Claim 11, wherein the pores of said porous polymeric matrix have pore diameters in the range 3 to 15 µm.
13. A test strip for an electrochemical sensor for contact with whole blood in order to effect an electrochemical measurement, said test strip having an exclusion layer in the form of a porous polymeric membrane with a mobile erythrocyte aggregating agent.
14. The test strip of Claim 13, which is an amperometric test strip having electrode areas overlain by said exclusion layer.
15. The test strip of Claim 14, wherein said exclusion layer has a thickness in the range 20 to 50 µm.
16. A method of manufacturing a test strip for an electrochemical sensor, said test strip having an erythrocyte exclusion membrane of polymeric material,, said method comprising the steps of providing a sprayable solution of said polymeric material, and spraying said sprayable solution to form said membrane in situ on said test strip.
CA002162045A 1993-05-12 1994-05-11 Electrochemical sensors Abandoned CA2162045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939309797A GB9309797D0 (en) 1993-05-12 1993-05-12 Electrochemical sensors
GB9309797.0 1993-05-12

Publications (1)

Publication Number Publication Date
CA2162045A1 true CA2162045A1 (en) 1994-11-24

Family

ID=10735356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162045A Abandoned CA2162045A1 (en) 1993-05-12 1994-05-11 Electrochemical sensors

Country Status (7)

Country Link
US (1) US5658444A (en)
EP (1) EP0698206B1 (en)
AU (1) AU6685694A (en)
CA (1) CA2162045A1 (en)
DE (1) DE69411732T2 (en)
GB (1) GB9309797D0 (en)
WO (1) WO1994027140A1 (en)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708247A (en) * 1996-02-14 1998-01-13 Selfcare, Inc. Disposable glucose test strips, and methods and compositions for making same
US6241862B1 (en) 1996-02-14 2001-06-05 Inverness Medical Technology, Inc. Disposable test strips with integrated reagent/blood separation layer
US7112265B1 (en) * 1996-02-14 2006-09-26 Lifescan Scotland Limited Disposable test strips with integrated reagent/blood separation layer
DE19605582A1 (en) * 1996-02-15 1997-08-21 Bayer Ag Graphite nonwovens as functional layers in diagnostic test kits
DE19605583A1 (en) 1996-02-15 1997-08-21 Bayer Ag Electrochemical sensors with improved selectivity and increased sensitivity
US5859537A (en) * 1996-10-03 1999-01-12 Dacco Sci, Inc. Electrochemical sensors for evaluating corrosion and adhesion on painted metal structures
JP3460183B2 (en) * 1996-12-24 2003-10-27 松下電器産業株式会社 Biosensor
DE69809391T2 (en) 1997-02-06 2003-07-10 Therasense Inc SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION
JP3297630B2 (en) 1997-07-28 2002-07-02 松下電器産業株式会社 Biosensor
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6752964B1 (en) * 1998-06-23 2004-06-22 California Institute Of Technology Polymer/plasticizer based sensors
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6565738B1 (en) * 1999-01-28 2003-05-20 Abbott Laboratories Diagnostic test for the measurement of analyte in abiological fluid
JP2002537031A (en) 1999-02-18 2002-11-05 バイオバルブ テクノロジーズ インコーポレイテッド Electroactive pores
DE19912120A1 (en) * 1999-03-18 2000-09-28 Fraunhofer Ges Forschung Procedure for the isolation of erythrocytes
US6696240B1 (en) 1999-10-26 2004-02-24 Micronix, Inc. Capillary test strip to separate particulates
US6319719B1 (en) 1999-10-28 2001-11-20 Roche Diagnostics Corporation Capillary hematocrit separation structure and method
WO2001038873A2 (en) * 1999-11-24 2001-05-31 Biotronic Technologies, Inc. Devices and methods for detecting analytes using electrosensor having capture reagent
US6406672B1 (en) 2000-01-28 2002-06-18 Roche Diagnostics Plasma retention structure providing internal flow
US6451264B1 (en) 2000-01-28 2002-09-17 Roche Diagnostics Corporation Fluid flow control in curved capillary channels
WO2001090733A1 (en) * 2000-05-23 2001-11-29 Radiometer Medical A/S A sensor membrane, a method for the preparation thereof, a sensor and a layered membrane structure for such sensor
WO2002010734A1 (en) * 2000-07-31 2002-02-07 Matsushita Electric Industrial Co., Ltd. Biosensor
WO2002010735A1 (en) * 2000-07-31 2002-02-07 Matsushita Electric Industrial Co., Ltd. Biosensor
DE10052066A1 (en) * 2000-10-19 2002-05-29 Inverness Medical Ltd Screen printable paste for the production of a porous polymer membrane for a biosensor
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7749174B2 (en) 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
EP1404234B1 (en) 2001-06-12 2011-02-09 Pelikan Technologies Inc. Apparatus for improving success rate of blood yield from a fingerstick
DE60234598D1 (en) 2001-06-12 2010-01-14 Pelikan Technologies Inc SELF-OPTIMIZING LANZET DEVICE WITH ADAPTANT FOR TEMPORAL FLUCTUATIONS OF SKIN PROPERTIES
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
ATE485766T1 (en) 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US6755949B1 (en) 2001-10-09 2004-06-29 Roche Diagnostics Corporation Biosensor
JPWO2003042679A1 (en) * 2001-11-14 2005-03-10 松下電器産業株式会社 Biosensor
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
CZ297082B6 (en) * 2002-06-03 2006-09-13 Ing. Ilja Krejcí-Engineering Three-dimensional components prepared by thick film technology and method of producing thereof
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US7767068B2 (en) 2002-12-02 2010-08-03 Epocal Inc. Heterogeneous membrane electrodes
US7842234B2 (en) * 2002-12-02 2010-11-30 Epocal Inc. Diagnostic devices incorporating fluidics and methods of manufacture
US7094330B2 (en) * 2002-12-02 2006-08-22 Epocal Inc. Heterogeneous membrane electrodes
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
DK1633235T3 (en) 2003-06-06 2014-08-18 Sanofi Aventis Deutschland Apparatus for sampling body fluid and detecting analyte
KR100554649B1 (en) * 2003-06-09 2006-02-24 주식회사 아이센스 Electrochemical biosensor
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US8007656B2 (en) * 2003-10-24 2011-08-30 Bayer Healthcare Llc Enzymatic electrochemical biosensor
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US7384791B2 (en) * 2004-01-21 2008-06-10 Hewlett-Packard Development Company, L.P. Method of analyzing blood
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8425858B2 (en) * 2005-10-14 2013-04-23 Morpho Detection, Inc. Detection apparatus and associated method
US20070086916A1 (en) * 2005-10-14 2007-04-19 General Electric Company Faceted structure, article, sensor device, and method
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
ITBO20060397A1 (en) * 2006-05-24 2007-11-25 Consiglio Nazionale Ricerche MACHINE FOR AUTOMATED MATERIAL DEPOSITION BY MEANS OF AN AIRBRUSH
WO2008079731A1 (en) * 2006-12-22 2008-07-03 Home Diagnostics, Inc. Gel formation to reduce hematocrit sensitivity in electrochemical test
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
CN102016596B (en) * 2008-03-27 2014-09-17 哈佛学院院长等 Paper-based microfluidic systems
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
CN102227636A (en) * 2008-09-30 2011-10-26 梅纳伊医疗科技有限公司 Sample measurement system
US20110210014A1 (en) * 2008-11-03 2011-09-01 Garosshen Thomas J Corrosion sensor system
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US20100213057A1 (en) 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
GB201005357D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
GB201005359D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP2583090B1 (en) 2010-06-15 2016-04-06 3M Innovative Properties Company Variable capacitance sensors and methods of making the same
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
KR101367262B1 (en) 2011-11-11 2014-02-26 주식회사 아이센스 Blood Glucose Sensor and sensing error detecting method using thereof
GB201207869D0 (en) * 2012-05-04 2012-06-20 Accunostics Ltd Pulsed signal testing of biological fluid
KR101466222B1 (en) 2012-06-01 2014-12-01 주식회사 아이센스 Electrochemical biosensor with improved accuracy
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
GB201302292D0 (en) * 2013-02-08 2013-03-27 Whatman Gmbh Medical diagnostic test systems,and a matrix therefor
JP7062272B2 (en) * 2018-03-06 2022-05-06 公立大学法人北九州市立大学 Sensor chip and its manufacturing method, analyzer, and analysis method
EP4317957A1 (en) * 2022-08-05 2024-02-07 Fundació Eurecat Additive manufacturing of sensors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662046A (en) * 1970-06-03 1972-05-09 Us Interior Method of making reverse osmosis membranes for desalination of water
DE3278334D1 (en) * 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US5509410A (en) * 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
CA1226036A (en) * 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
DE3323973A1 (en) * 1983-07-02 1985-01-03 Boehringer Mannheim Gmbh, 6800 Mannheim ERYTHROCYTE RETENTION SUBSTRATES
CA1249025A (en) * 1984-10-12 1989-01-17 Anthony E.G. Cass Chemical sensor for n-acetyl primary aromatic amines
GB8531755D0 (en) * 1985-12-24 1986-02-05 Genetics Int Inc Assay for cholestrol & derivatives
GB8709882D0 (en) * 1987-04-27 1987-06-03 Genetics Int Inc Membrane configurations
JPH02140147A (en) * 1988-01-19 1990-05-29 Syntex Usa Inc Method and apparatus for separating blood plasma from red corpuscle
US5306623A (en) * 1989-08-28 1994-04-26 Lifescan, Inc. Visual blood glucose concentration test strip
AU640162B2 (en) * 1989-08-28 1993-08-19 Lifescan, Inc. Blood separation and analyte detection techniques
DE4015589A1 (en) * 1990-05-15 1991-11-21 Boehringer Mannheim Gmbh DEVICE AND THE USE THEREOF FOR SEPARATING PLASMA FROM WHOLE BLOOD
US5166051A (en) * 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes

Also Published As

Publication number Publication date
WO1994027140A1 (en) 1994-11-24
DE69411732T2 (en) 1999-02-25
EP0698206B1 (en) 1998-07-15
US5658444A (en) 1997-08-19
GB9309797D0 (en) 1993-06-23
EP0698206A1 (en) 1996-02-28
AU6685694A (en) 1994-12-12
DE69411732D1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
CA2162045A1 (en) Electrochemical sensors
US4886740A (en) Enzyme-electrode sensor with organosilane treated membrane
US4240889A (en) Enzyme electrode provided with immobilized enzyme membrane
JP3220486B2 (en) Visible test strip for blood glucose concentration
JP4763777B2 (en) Enzyme sensor comprising a cover membrane layer coated with a hydrophilic polymer
EP0359831B1 (en) Biosensor and process for its production
US6436255B2 (en) Biosensor
US5229282A (en) Preparation of biosensor having a layer containing an enzyme, electron acceptor and hydrophilic polymer on an electrode system
CN101184851B (en) Enzyme sensor including a water-containing spacer layer
FI91331C (en) Sensor
JP3406089B2 (en) Dry analytical element containing amphoteric electrolyte
US20030125403A1 (en) Paste, which can undergo screen printing, for producing a porous polymer membrane for a biosensor
CZ227697A3 (en) Diagnostic test carrier and the use thereof
EP0442969A1 (en) Wholly microfabricated biosensors and process for the manufacture and use thereof
CN108291889B (en) Outer layer for enzyme sensor
DE2638193C3 (en) Laminated membrane for use in an enzyme electrode and method of making such a membrane
EP0859954B1 (en) Biosensors comprising a membrane
JP3285879B2 (en) Sensor and modified membrane for this sensor
EP0546032B1 (en) Immobilization of organic macromolecules or biopolymers in a polymer membrane
CN112014448A (en) Biosensor, method for manufacturing the same, and polymer film layer for biosensor
JP4493535B2 (en) Test paper
WO1988009824A1 (en) Improvements in diagnostic test strips
DE102004003793A1 (en) Reagent-carrying layer for electrochemical biosensors, e.g. for detecting substances such as creatinine in body fluids, comprises a layer of reagent-containing polymer and a thin, water-resistant, permeable surface layer
US8202490B2 (en) Membranes and methods for coating membranes
US7816112B2 (en) Castable diffusion membrane for enzyme-based sensor application

Legal Events

Date Code Title Description
FZDE Discontinued